Andrew Clark: Senior Independent Non-Executive Director
Dr. Clark was appointed to the Board of the Company in September 2007. He received his Ph.D. in Neuroscience from St. Andrew's University and was a post-doctoral research fellow in pharmacology at the University of Oxford. He worked in London as a biotech analyst at Baring Securities. In 1995, Andrew co-founded Reabourne Ltd, an investment management business focused on small capitalization technology and biotechnology companies, acting as portfolio manager. He left Reabourne in 2003 following the sale of the business, and currently works as a consultant in the biotechnology field. He has held a number of non-executive directorships with life-science and investment companies.
John Garcia: Chairman, Independent Non-Executive Director
Mr. Garcia was appointed to the Board of the Company in September 2007. With a 25-year career in the health products industry, he has been instrumental In the development and growth of several medical products and services companies. He served for more than ten years as President of Sulzermedica’s US$300 million pacemaker business before it was acquired by Guidant in 1998. He also held sales and marketing management positions with FHP (a California HMO), Bio Science (a national reference lab) and Pharmaseal (a division of American Hospital Supply Corporation).
Eric Swenden: Non-Executive Director
Mr. Swenden was appointed to the Board of the Company in 2003. He has enjoyed a long and successful career in finance and company management, having held positions on the boards of several public companies, including Vandemoortele Food Group and General Bank (Belgium's largest bank before its merger with Fortis).
Responsibilities of the Audit Committee
The Audit Committee is responsible for ensuring that the financial performance of Lifeline Scientific is properly measured and reported on, and for reviewing reports from the auditors relating to the accounts and internal controls.